Short answer
Eledon Pharmaceuticals, Inc. (ELDN) filed its Q1 2026 10-Q quarterly report on May 13, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$39M
- −500.8% YoY
- EPS (diluted)
- −$0.33
- −312.5% YoY
Source: XBRL data from the Eledon Pharmaceuticals, Inc. (ELDN) Q1 2026 10-Q on SEC EDGAR. USD.
Eledon Pharmaceuticals, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Clinical-stage biotechnology company focused on tegoprubart; no product revenue, segment revenue, or YoY quarterly revenue figures disclosed
- BESTOW eGFR approximately 69 vs 66 mL/min/1.73 m² for tacrolimus at 12 months
- 2026 outlook: seek FDA guidance on potential Phase 3 kidney-transplant trial; ALS development requires additional financing
Risk Factors
- FDA rulemaking pause under Trump administration executive order, creating uncertainty around finalized rules affecting development and commercialization
- Phase 3 kidney-transplant trial and potential islet-cell study require substantial additional capital
- Net loss $39.0 million for Q1 2026 with cash and short-term investments of $111.1 million
- Clinical-trial delays from enrollment, manufacturing, regulatory holds, or contractor noncompliance threatening tegoprubart timelines
- 51,781,090 shares issuable under outstanding warrants, creating significant dilution risk to current stockholders
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Eledon Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.